Compare FRPH & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRPH | ASMB |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.6M | 442.9M |
| IPO Year | 1995 | 2010 |
| Metric | FRPH | ASMB |
|---|---|---|
| Price | $23.27 | $24.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | 79.2K | ★ 179.9K |
| Earning Date | 04-10-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,846,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $638.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.57 | N/A |
| 52 Week Low | $20.53 | $15.25 |
| 52 Week High | $27.98 | $39.71 |
| Indicator | FRPH | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 62.16 | 36.04 |
| Support Level | $23.10 | $20.23 |
| Resistance Level | $24.59 | $31.21 |
| Average True Range (ATR) | 0.70 | 1.80 |
| MACD | 0.12 | -0.30 |
| Stochastic Oscillator | 90.51 | 2.96 |
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, industrial, and office (the Development Segment), and (iv) management of mixed-use residential/retail properties owned through joint ventures.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.